<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04843813</url>
  </required_header>
  <id_info>
    <org_study_id>2001-2</org_study_id>
    <nct_id>NCT04843813</nct_id>
  </id_info>
  <brief_title>Effects of Lutein Supplementation on Cognition and MPOD in Multiple Sclerosis Patients-</brief_title>
  <acronym>LuMES</acronym>
  <official_title>Lutein and Multiple Sclerosis Experimental Study (LuMES)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Urbana-Champaign</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Division of Nutritional Sciences, University of Illinois at Urbana-Champaign</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health Rehabilitation Research Resource to Enhance Clinical Trials (REACT)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Illinois at Urbana-Champaign</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The central hypothesis is that lutein supplementation will improve MPOD and cognition.&#xD;
      Accordingly, the specific aims are to 1) to determine the process feasibility associated with&#xD;
      participating in 4-month lutein supplementation trial; and 2) to investigate the scientific&#xD;
      feasibility of 4-month daily lutein supplementation on biological markers of lutein status&#xD;
      and cognitive function among persons with MS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A two-group parallel design will be employed whereby participants will be randomly assigned&#xD;
      to one of 2 groups. The supplementation doses 20mg/d (Group 1), and placebo (Group 2) will be&#xD;
      consumed daily by the participant for a 4-month period. Pre-test and follow-up measures of&#xD;
      lutein status and cognitive function will be assessed at baseline and at 4-month follow-up&#xD;
      via laboratory visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A 2-group parallel design will be employed to collect feasibility data on daily lutein supplementation over 4 months.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Macular Pigment Optical Density</measure>
    <time_frame>4 months (baseline vs. follow-up)</time_frame>
    <description>Changes in Macular Pigment Optical Density (log units) between groups using a macular densitometer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Attentional Accuracy</measure>
    <time_frame>4 months (baseline vs. follow-up)</time_frame>
    <description>Changes in accuracy (%) between groups using a computerized flanker task</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Attentional Reaction Time</measure>
    <time_frame>4 months (baseline vs. follow-up)</time_frame>
    <description>Changes in reaction time (ms) between groups using a computerized flanker task</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Attentional Resource Allocation</measure>
    <time_frame>4 months (baseline vs. follow-up)</time_frame>
    <description>Changes in P3 event related potential amplitude (microvolts) between groups using a computerized flanker task</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Attentional Processing Speed</measure>
    <time_frame>4 months (baseline vs. follow-up)</time_frame>
    <description>Changes in P3 event related potential latency (ms) between groups using a computerized flanker task</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Lutein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Safflower Oil</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lutein</intervention_name>
    <description>Participants will consume daily soft gels containing the lutein supplement.</description>
    <arm_group_label>Lutein</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will consume daily soft gels containing the safflower oil.</description>
    <arm_group_label>Safflower Oil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-64.9 years&#xD;
&#xD;
          -  Self-reported relapsing-remitting MS (RRMS) diagnosis&#xD;
&#xD;
          -  Expanded Disability Status Scale (EDSS) score between 0-3.5&#xD;
&#xD;
          -  Macular Pigment Optical Density at baseline (MPOD ≤0.35)&#xD;
&#xD;
          -  Score ≤55 during the Symbol Digit Modalities Test (SDMT)&#xD;
&#xD;
          -  20/20 or corrected vision&#xD;
&#xD;
          -  No presence of color blindness&#xD;
&#xD;
          -  No history of age-related macular degeneration&#xD;
&#xD;
          -  No history of epileptic seizures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Under 18 years or over 64.9 years&#xD;
&#xD;
          -  MS diagnosis other than RRMS&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Uncorrected vision&#xD;
&#xD;
          -  Presence of color blindness&#xD;
&#xD;
          -  PDDS score of 7 or more&#xD;
&#xD;
          -  Prior diagnosis of age-related macular degeneration&#xD;
&#xD;
          -  History of epileptic seizures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naiman Khan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois Urbana Champaign</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Naiman Khan, PhD, RD</last_name>
    <phone>217-300-2197</phone>
    <email>nakhan2@illinois.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Illinois at Urbana-Champaign</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naiman A Khan, PhD, RD</last_name>
      <email>nakhan2@illinois.edu</email>
    </contact>
    <investigator>
      <last_name>Naiman A Khan, PhD, RD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 7, 2021</study_first_submitted>
  <study_first_submitted_qc>April 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2021</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Urbana-Champaign</investigator_affiliation>
    <investigator_full_name>Naiman Khan</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Cognitive Function</keyword>
  <keyword>Lutein</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

